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Abstract 
Background: Differences between the arms in systolic blood pressure [SBP] of ≥10 mm 
Hg have been associated with an increased risk of mortality in patients with 
hypertensive and chronic renal disease. For the first time, we examined these 
relationships in a non-clinical population. 
Design: Cohort study. 
Methods: Participants were 4419 men [mean age, 38.37] from the Vietnam Experience 
Study. Bilateral SBP and diastolic BP [DBP], serum lipids, fasting glucose, erythrocyte 
sedimentation rate [ESR], metabolic syndrome, and ankle brachial index were assessed 
in 1986.  
Results: Ten percent of men had an interarm difference of ≥10 and 2.4% of ≥15 mmHg. 
A 15-year follow-up period gave rise to 246 deaths [64 from cardiovascular disease 
[(CVD)]. Interarm differences of ≥10 mm Hg were associated with an elevated risk of 
all-cause [hazard ratio (HR) = 1.49, 95% confidence interval (CI), 1.04 – 2.14] and 
CVD mortality [HR = 1.93, 95% CI, 1.01 – 3.69]. After adjusting for SBP, DBP, lipids, 
fasting glucose and ESR, associations between interarm differences of ≥10 mm Hg and 
all-cause (HR=1.35, 95% CI = 0.94 – 1.95) and CVD mortality (HR = 1.62, 95% CI, 
0.84 - 3.14) were significantly attenuated.  
Conclusions: In this non-clinical cohort study, interarm differences in SBP were not 
associated with mortality after accounting for traditional CVD risk factors. Interarm 
differences might not be valuable as an additional risk factor for mortality in 
populations with a low risk of CVD.   
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 Introduction 
A marked difference in SBP between the arms have been linked to subclavian stenosis,1, 
2 atherosclerotic plaque,3 and are most commonly observed in patients with 
hypertension,4 diabetes,5 and chronic renal disease,1 suggesting interarm differences are 
a marker of peripheral vascular disease.6 The presence of an interarm difference has 
been linked to the delayed diagnosis7 and poor control of hypertension,8 and as such are 
recommended in screening guidelines on the assessment of hypertension.9,10 Despite 
these associations, few cohorts record information on SBP in both arms and as a result 
associations with mortality are unclear. A small number of studies have shown 
differences of ≥ 10mm Hg between the arms in SBP are associated with an increased 
risk for all-cause 4, 6 and CVD mortality in high risk patients (e.g. hypertension, 4, 11 
chronic renal disease 1). However, owing to a paucity of data, the extent to which these 
results are apparent in non-clinical groups is unclear.  
Accordingly, the aim of the present study was to examine whether interarm 
differences in SBP are associated with all-cause and cardiovascular disease mortality 
over a 15-year follow-up period in a cohort of middle aged men. In addition to 
examining the link, if any, between interarm differences in blood pressure and 
mortality, we also test whether incorporating information on interarm differences into 
an established risk score for CVD (the Framingham risk algorithm) 12 will improve its  
predictive capacity for all-cause and CVD mortality.  
Methods 
Study design and participants 
Participants were drawn from the Vietnam Experience Study. The Vietnam Experience 
Study is a prospective cohort of United States army veterans that was established in 
1983 to compare the health of men who participated in the Vietnam war against those 
who did not. 13 Briefly, on 31st December 1983, 18 313 men were drawn randomly from 
5 million records of men who served in Vietnam and elsewhere. Of those men who 
were traced, 15 288 (85.6% response) participated in a telephone survey in 1985. A 
random sample was taken of telephone survey respondents in 1986 and 4462 (69.3% of 
those invited) attended a 3-day medical examination. Ethical approval for the study 
protocol was given by the US Office for Technology Assessment, the Department of 
Health and Human Sciences Advisory Committee, the Agent Orange Working Group 
Science Panel, and a review panel from the US Centers for Disease Control. 
 
Assessment of Interarm differences in Blood Pressure 
Blood pressure was assessed after participants were seated for at least 2 minutes, with a 
standard mercury sphygmomanometer. Research nurses were instructed to ensure each 
arm was supported during measurements, free of clothing, and only to take 
measurements when men appeared relaxed and comfortable. Measurements were made 
twice in both arms in an alternating sequence: right arm, left arm, right arm, left arm. 
Standard or large cuffs were used as appropriate. 14 Interarm differences in SBP were 
similar for the first (M = 1.00 mmHg; 95% CI = 0.76, 1.21) and second pair of 
assessments (M = 1.05 mmHg; 95% CI = 0.80, 1.29). Readings were averaged to obtain 
a mean SBP for each arm, which was then used to calculate an interarm difference 
(mean of right arm minus mean of left arm).  
 
Assessment of Risk Factors for Cardiovascular Disease Mortality 
Blood samples were taken in the morning after participants had fasted from 19:00 the 
previous day. Levels of triglycerides, cholesterol fractions and urinary creatinine were 
ascertained using a Kodak Ektachem 700 AutoAnalyzer (Eastman Kodak, Rochester, 
New York). Serum glucose level was determined with an adaptation of the glucose 
oxidase-peroxidase-chromogen-coupled system for glucose determination in biological 
fluids. Erythrocyte sedimentation rate (ESR) was measured using the Westergen 
method. Height and weight were measured from which body mass index (BMI) was 
calculated.  
We defined the metabolic syndrome using a modified version of the Adult 
Treatment Panel III criteria (using BMI ≥30 kg/m2 instead of waist circumference, 
regarded by the WHO as an acceptable substitute).15, 16 Diabetes status was defined as 
having a fasting plasma glucose ≥7.0 mmol/L and/or use of medication for diabetes.17 
Hypertension was defined using the JNC 7 cut-points for systolic/diastolic blood 
pressure ≥140/≥90 mmHg, or use of antihypertensive medication. 9 Men underwent a 
separate examination of the peripheral arterial system to calculate the ankle brachial 
index (ABI) using the Doppler technique. ABI for each leg was calculated by dividing 
the ankle systolic pressure by the higher of the right and left brachial systolic pressures 
obtained during this examination, and we used the lower of the left and right leg indices 
in the analysis, as an indicator of worse disease. Low ABI was defined as ABI ≤0.9.  18 
Scores for the risk of coronary heart disease (CHD) at 10 years were calculated 
using the Framingham equation with information on age, sex, total cholesterol levels, 
high-density lipoprotein (HDL) cholesterol levels, SBP, and smoking habits. 12 
Ascertainment of All cause and Cardiovascular Disease Mortality 
Information on deaths was collected for 15 years after the 1986 medical examination. 
Mortality was ascertained using databases supplied by the US army: the Veterans 
Administration (Beneficiary Identification and Records Locator Subsystem), the Social 
Security Administration, the Internal Revenue Service, and the National Center for 
Health Statistics (National Death Index). Events were defined as deaths from all-causes 
and those resulting from major cardiovascular disease (ICD-9: 390–434,436–448, ICD-
10: I00–I78). A previous analysis found the standardized (for age, race and calendar 
year) mortality ratios of VES participants were comparable to those of an equivalent US 
male population. 19 
Statistical Analysis 
We compared participants’ characteristics using ANOVA, Chi-square (χ 2) and the 
Kruskall-Wallis test according to interarm differences in SBP of 0 – 4.9, 5 – 9.9, 10 - 
14.9 and ≥15 mmHg. We examined the proportional hazards assumption graphically for 
each interarm difference in SBP with all-cause and CVD mortality and found no 
evidence for violation. We therefore used Weibull regression analysis to examine the 
association between interarm differences and mortality (for all causes and 
cardiovascular disease). This model is a parametric form of the Cox proportional 
hazards model and accounts for the differing lengths of follow-up among participants. 
This model also allows researchers to calculate the risk for mortality during a fixed 
period of time (t) as r(t) 1 – exp(– exp[(log(t) – Xβ)/ σ]), where X is the vector of risk 
factors, β is the vector of coefficients, and σ is the estimated scale parameter. This 
model has been used previously in the Framingham Heart Study and to describe the 
effect of adding new risk factors for CVD to the Framingham risk score. 20 
Interarm SBP difference was fitted as a continuous term (per 10 mmHg) and in 
separate models, using categories of <5 vs. ≥5 mmHg, <10 vs. ≥10 mmHg, and <15 vs. 
≥ 15 mmHg. Hazard ratios and accompanying 95% CIs were sequentially adjusted for a 
series of potential confounding factors previously associated with peripheral vascular 
disease 6 and CVD mortality. 21, 22 Adjustments were made for: obesity, smoking status, 
units of alcohol per week, and ethnic group (model 2); model 2 plus mean SBP and 
DBP (from the 4 measurements of SBP and DBP), metabolic syndrome, triglyceride, 
HDL-cholesterol, glucose, ESR and creatinine (model 3); model 3 plus ABI (≤0.9 vs 
>0.9; model 4); and model 4 plus the Framingham Risk Score (model 5). We modelled 
an interaction between interarm differences at each cut-point and hypertension status to 
examine whether associations were different in hypertensive men, as significant 
associations have been found in hypertensive patients before. 4, 11 
We also calculated the hazards for mortality using a Weibull model that included 
the Framingham Risk Score and interarm differences in SBP (at ≥5, ≥10, and ≥15 
mmHg) and compared it to a model that only included the Framingham Risk Score. We 
examined discrimination across the 2 models by using Harell’s c-index adjusted for 
optimism using 100 bootstrap repetitions 23; an overall (likelihood ratio chi-square test) 
and penalized assessment of model fit (Akaike’s Information Criterion 24, and the Bayes 
Information Criterion) 25. We chose these measures of discrimination rather than the net 
reclassification improvement index 26, as there was a low number of deaths in men with 
high Framingham risk scores.  
We then estimated the effect on the hazard ratio of adjusting for a particular 
covariate using the following formula: ([Hazard Ratio adjusted for age and ethnicity − 1] − 
[Hazard Ratio adjusted for age and ethnicity plus covariate − 1]/[Hazard Ratio adjusted for age and ethnicity − 
1]) X 100. All analyses were performed with Stata, version 11.0 using 2-sided tests with 
a significance level of P<0.05. 
Results 
Of the 4462 men eligible for inclusion, 4419 (99.03%) featured in the analytical sample. 
The 43 men who attended the medical examination but were excluded due to having 
missing values for some variables had a lower mean DBP (87.01 vs. 84.09 mmHg; P = 
0.04) and ESR (41.63 vs. 36.90 mm/h; P = 0.03) but were similar in other respects. 
Supplementary material online, eTable 1, shows that relative to study members not 
selected for the medical examination, men included in the analytical sample were more 
likely be obese (12.7 % vs. 11.5%), but generally differences in characteristics between 
men included and excluded were small.  
Table 1 shows the characteristics of the 4419 participants. A total of 1667 
(37.7%) men had a mean interarm difference in SBP of ≥5, 435 (9.8%) of ≥10, 107 
(2.4%) of ≥15 and 24 (0.5%) of ≥20 mmHg. The mean interarm difference in SBP was 
1.03 mm Hg (95% CI = 0.83, 1.22), and was higher in the right arm. Interarm 
differences in SBP were positively associated with mean SBP (0 – 4.9 mm Hg: M = 
122.7 vs. ≥15 mm Hg: M = 128.25; P < 0.001) and DBP (0 – 4.9 mm Hg: M = 83.79 vs. 
≥15 mm Hg: M = 85.71; P = 0.01) and differences of 10 and 15mmHg were more 
common in men with hypertension (P <0.001), an ABI ≤0.9 (P = 0.01), and those who 
were obese (P = 0.04). There was, however, no evidence that interarm differences were 
associated with glucose levels, being defined as having diabetes, or metabolic syndrome 
(Table 1). 
A mean of 14.9 years of follow-up (range 0.03 - 15.00) gave rise to 246 (5.60%) 
deaths in total of which 64 (26.01%) were due to cardiovascular disease. Table 2 shows 
that in the unadjusted regression models, the hazard ratios for all cause mortality among 
men with an interarm difference in SBP of >5, >10 and > 15mm Hg were 1.30 (95% CI, 
1.01 to 1.67), 1.49 (95% CI, 1.04 to 2.14) and 1.37 (95% CI, 0.68 to 2.77) respectively, 
with stronger associations apparent for cardiovascular disease mortality: for >5 mmHg: 
HR=1.66, 95% CI, 1.02 to 2.71; >10 mmHg: HR=1.93, 95% CI: 1.01 to 3.69; 
>15mmHg HR= 2.00, 95% CI, 0.63 to 6.39. When interarm difference was fitted as a 
continuous term (per 10 mmHg), there was positive association with both all-cause (HR 
=1.13, 95% CI, 1.01 to 1.27) and cardiovascular disease mortality (HR =1.14, 95% CI, 
0.92 to 1.40) in the fully adjusted analysis (see supplementary eTable 2 online). 
Following adjustment for established risk factors for CVD, including the 
Framingham risk score the adjusted hazard ratios (model 5) for interarm differences of 
>10 mm Hg were significantly attenuated, with hazard ratios of 1.35 (95% CI =0.94 to 
1.95) for all-cause and 1.62 (95% CI, 0.84 to 3.14) for cardiovascular disease mortality. 
Supplementary material online, eTable 3, shows separate adjustments for factors 
associated with lifestyle (smoking status, units of alcohol per week, obesity status) at 
the baseline assessment explained little of the attenuating effect on these associations. In 
general, adjustment for hypertension status (all cause mortality: 6 – 25%), metabolic 
syndrome (all cause mortality: 6 – 22%), and the Framingham risk score (all cause 
mortality: 16 – 33%) were associated with the largest percentage reduction in 
associations between interarm differences and mortality.   
Harrell’s C-indices indicated a moderate level of discrimination but estimates 
were not significantly different across the Framingham risk scores and Framingham 
plus interarm difference models. There was also little change in the penalized measures 
of model fit between the Framingham risk scores and Framingham plus interarm 
difference models (see supplementary material online, eTable 4). Interactions between 
interarm differences at 5, 10, and 15 mm Hg and hypertension status were also non-
significant at each cut-point for all-cause and CVD mortality (P>0.05; data not 
tabulated). 
Discussion 
In a cohort of nearly 4500 men, an interarm difference in systolic blood pressure 
of 10 mmHg or more was associated with an increased risk for cardiovascular disease 
and all cause mortality. This association was, however, significantly attenuated after 
adjustment for established cardiovascular disease risk factors. In regard to explanatory 
factors, smoking status, units of alcohol per week and obesity, played little or no part in 
the associations between interarm differences and mortality. Ankle brachial index, a 
measure of peripheral artery disease, had a small but modest effect on the interarm 
difference-mortality association. Adjustment for hypertension, metabolic syndrome, and 
in particular Framingham risk scores at the baseline assessment had the strongest 
attenuating effects on the interarm difference – mortality association. Consistent with 
this finding, we found interarm differences did not improve upon the Framingham risk 
score in the prediction of mortality.  
We identified one recent meta analysis 6 and two cohort studies 4, 27 not included 
in the meta-analysis that examined the association between interarm differences in SBP 
and all-cause and cardiovascular disease mortality in patients with hypertension4 and 
renal disease. 27 A positive association was reported in the meta analysis between all-
cause mortality and an interarm difference of 10 mmHg or more in SBP (pooled HR for 
2 cohorts = 1.90 (95% CI, 0.8 to 4.7); 8, 11 and two cohorts not included in this meta 
analysis reported results of a similar magnitude. 4, 27 One cohort of hypertensive patients 
reported larger hazards for CVD than all-cause mortality after five (HR = 2.8, 95% CI, 
0.9 to 9.2) 11 and ten years of follow-up (HR = 4.2, 95% CI, 1.7 to 10.8), 2, 3, 4, 7 , 12  with 
a similar pattern reported in a cross-sectional analysis of patients undergoing 
haemodialysis.27 In contrast to these findings, we did not find an association between 
interarm differences in SBP and mortality. This inconsistency may in part be attributed 
to our deliberate selection of a low-risk cohort characterized by a comparatively low 
prevalence of hypertension, metabolic syndrome and other CVD risk factors. This 
resulted in a lower event rate and smaller interarm differences than have been reported 
in previous studies with hypertensive patients. 4, 11 In support of this assertion, we found 
a lower proportion of men with interarm differences at 10 mmHg or more (13.1 vs. 
24.0%) and 15 mmHg or more (3.9 vs. 9.0%)4  and a lower proportion of deaths in the 
present cohort (all-cause mortality: 5.4 vs. 25.7%). 4  
Despite these differences in sample characteristics, one study with hypertensive 
patients reported large hazard ratios for the interarm difference - mortality association 
even after adjusting for the Framingham risk score (difference of 10 mm Hg in SBP: 
HR = 2.2; 95% CI = 1.4 to 3.6).4 This suggests a mechanism by which interarm 
differences increase the risk for mortality which does not involve factors included in the 
Framingham risk score; and that this factor was not present in our cohort. Interarm 
differences have been conceptualised, and are associated with a measure of peripheral 
artery disease, the ankle brachial index. 1, 2 However, we found a low ABI indicative of 
peripheral artery disease did not explain associations between interarm differences and 
mortality. It is therefore possible that the cut-point we used on the ABI  lacks predictive 
validity, or interarm differences are indicative of another comorbidity in hypertensive 
patients not adequately captured by traditional CVD risk factors. 
The strengths of this study are its size, being larger than previous studies on 
interarm difference, and tracking of participants over a 15-year period. This allowed us 
to evaluate the prognostic value of interarm differences over a period in middle age 
where screening for hypertension typically starts. The non-clinical recruitment meant 
we could examine associations in a low-risk population for the first time and the 
comprehensive measurement of CVD risk factors allowed us to address concerns that 
interarm differences might not add anything over routine CVD risk factor assessment.  
This study is not, however, without limitations. First, the sequential method of 
recording blood pressure we used may have produced larger interarm differences than 
simultaneous readings. 28, 29 Although, little difference has been found between these 
methods in estimates of the association of interarm differences with ABI, or all-cause 
mortality.6 Second, we did not have data on women, and all investigations to date have 
been in cohorts in middle to old age, 1,4, 8, 11, 27 thus further testing is needed to confirm 
associations in these groups. It is also worth noting that despite not adding to the 
prediction of mortality, assessment of blood pressure in both arms may have clinical 
value by increasing the sensitivity of diagnosis and management of hypertension 
through the use of measurements from the arm with the highest reading. Additional 
studies, ideally a controlled clinical trial, are needed to assess whether incorporating bi-
lateral brachial assessments into screening for hypertension in primary care, would 
improve the identification and management of individuals at risk for a CHD event. In 
conclusion, we found that interarm differences were associated with survival over a 15 
year period in men with a low risk of CVD, but that these associations were explained, 
in part, by traditional CVD risk factors. As these risk factors are already part of routine 
CVD risk screening, interarm differences may not offer anything over established risk 
prediction algorithms, such as the Framingham risk score, in the prediction of mortality 
in populations with a low risk of CVD.  
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Table 1. Characteristics of participants according to interarm differences in systolic 
blood pressure in the Vietnam Experience Study (1986). 
a Other group = Hispanics, Asians, Pacific Islanders, American Indians, and Alaskan Natives; 
b  Normotensive: systolic blood pressure <140mmHg and diastolic blood pressure <90mmHg; 
Hypertensive: systolic blood pressure >140 mmHg or diastolic blood pressure >90 mm Hg or 
on hypertension medication (the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criterion) or any 
hypertension medication; c Fasting blood glucose ≥ 7.0 mmol/l or on medication for diabetes; 
d Modified version of the Adult Treatment Panel III diagnostic criteria using BMI≥30 instead 
of waist circumference. e BMI≥30 kg/m2. Abbreviations: BMI: body mass index; HDL: high-
density lipoprotein; IQR: interquartile range; SD: standard deviation.  
 Interarm difference in systolic blood pre    
 0 – 4.9 (n=2752) 5 – 9.9 (n=1 232) 10 – 14.9 (n=328       
Continuous variables      
Age (Years), Mean (SD) 38.36 (2.51) 38.27 (2.49) 38.23 (2.57)    
Systolic Blood Pressure (mm Hg), Mean (SD) 122.27 (11.57) 123.76 (12.23) 124.27 (12.92)    
Diastolic Blood Pressure (mm Hg), Mean (SD) 83.79 (9.20) 84.40 (9.36) 84.98 (10.26)    
Glucose (mmol/l), Mean (SD) 5.22 (0.93) 5.21 (0.84) 5.34 (1.47)    
Triglycerides (mg/dL), Median (IQR) 1.01 (0.70, 1.51) 1.01 (0.69, 1.46) 1.08 (0.76, 1.57)     
HDL Cholesterol (mg/dL), Mean (SD) 1.16 (0.33) 1.15 (0.30) 1.13 (0.29)    
Erythrocyte sedimentation rate (mm/h),  Mean 
 
36.78 (17.15) 36.71 (17.28) 37.38 (17.13)    
Creatinine (mg/dL), Mean (SD) 1.11 (0.18) 1.11 (0.18) 1.10 (0.18)    
Alcohol intake (units per week), Median (IQR) 2.00 (0.00, 9.00) 2.00 (0.00, 8.00) 2.00 (0.00, 9.00)     
Categorical variables       
Ethnic group, % (Number)       
    White 81.9 (2 253) 83.1 (1 024) 78.4 (257)    
    Black 11.8 (325) 11.5 (142) 12.8 (42)    
    Other a 6.3 (174) 5.4 (66) 8.8 (29)    
Hypertension status, % (Number) b 27.9 (768) 28.6 (352) 36.0 (118)    
Ankle brachial index 0.9, % (Number) 3.3 (92) 3.7 (46) 4.3 (14)    
Diabetes status, % (Number) c 2.1 (57) 1.7 (21) 2.4 (8)    
Metabolic syndrome, % (Number) d  15.8 (435) 14.5 (179) 18.3 (60)    
Obesity, % (Number) e 12.1 (334) 12.6 (155) 17.1 (56)    
Current smoker, % (Number) 44.1 (1 214) 41.7 (514) 44.8 (147)    
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Table 2. Unadjusted and adjusted hazard ratios (95 % confidence interval) for all-cause 
and cardiovascular disease mortality at the cut-points of >5, >10 or > 15mm Hg in 
systolic blood pressure (n = 4419) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model a Interarm difference All deaths (n=246) Cardiovascular deaths (n=64) 
  HR 95 % CI P value HR 95 % CI P value 
   ref b    ref b   
1  >5 1.30 1.01, 1.67 0.04 1.66 1.02, 2.71 0.04 
 >10 1.49 1.04, 2.14 0.03 1.93 1.01, 3.69 0.04 
 >15 1.37 0.68, 2.77 0.38 2.00 0.63, 6.39 0.24 
        
2 >5 1.30 1.01, 1.67 0.04 1.67 1.02, 2.71 0.04 
 >10 1.43 1.00, 2.06 0.05 1.84 0.96, 3.53 0.07 
 >15 1.53 0.75, 3.09 0.24 2.13 0.67, 6.82 0.20 
        
3 >5 1.28 0.99, 1.65 0.04 1.61 0.98, 2.64 0.06 
 >10 1.37 0.95, 1.98 0.09 1.69 0.87, 3.25 0.12 
 >15 1.38 0.67, 2.82 0.37 1.86 0.57, 6.04 0.30 
        
4 >5 1.28 0.99, 1.65 0.06 1.61 0.98, 2.64 0.06 
 >10 1.35 0.94, 1.95 0.11 1.67 0.87, 3.23 0.12 
 >15 1.28 0.62, 2.62 0.50 1.85 0.57, 6.04 0.30 
        
5 >5 1.28 0.99, 1.65 0.06 1.56 0.95, 2.56 0.08 
 >10 1.35 0.94, 1.95 0.11 1.62 0.84, 3.14 0.15 
 >15 1.28 0.62, 2.63 0.50 1.62 0.49, 5.34 0.43 
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HR = hazard ratio; CI = confidence interval.  a Model 1 = Unadjusted; Model 2 = model 1 + 
BMI ≥30 kg/m2, smoking status, alcohol intake (units per week), ethnic group; Model 3 = 
model 2+, systolic blood pressure, diastolic blood pressure, metabolic syndrome, 
triglycerides, HDL cholesterol, glucose, erythrocyte sedimentation rate; Model 4 = model 3 + 
ankle brachial index 0.9; Model 5 = model 4 + Framingham Risk Score. b Reference 
category = interarm difference in systolic blood pressure <5; <10; <15 depending on the 
analysis. 
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Table 1. Comparison of participants included in the analysis from the medical study (n=4419) to those who only participated in the 
telephone survey (n = 13 791) 
 
 
 
 
 
 
 
 
 Included in analytical sample (n=4419) 
Telephone survey sample  
(n= 13 791)  
P value 
Continuous variables    
Age (Years), Mean (SD) 37.92 (2.50) 37.95 (2.47) 0.51 
Alcohol intake (units per week), Median 
(IQR) 2.00 (0.00, 9.00) 2.00 (0.00, 9.00) 
0.61 
Categorical variables     
Ethnic group, % (Number)     
    White 82.0 (3,623) 82.9 (8,928)  
    Black 11.7 (517) 10.8 (1,161)  
    Other a 6.3 (279) 6.3 (677) 0.26 
Obesity, % (Number) e 12.7 (563) 11.5 (1,241) 0.04 
Current smoker, % (Number) 43.3 (1,913) 44.7 (4,811) 0.11 
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Table 2. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) for mortality per 10 mm Hg difference 
in systolic blood pressure among participants  
 
 
 
 
 
 
 
 
a Model 1 = Unadjusted; Model 2 = model 1 + BMI ≥30 kg/m2, smoking status, alcohol intake (units per week), ethnic group; Model 3 = model 2+, systolic 
blood pressure, diastolic blood pressure, metabolic syndrome, triglycerides, HDL cholesterol, glucose, erythrocyte sedimentation rate; Model 4 = model 3 + 
ankle brachial index 0.9; Model 5 = model 4 + Framingham Risk Score. b Reference category = interarm difference in systolic blood pressure <5; <10; <15 
depending on the analysis. 
Model a All deaths (n=246) Cardiovascular deaths 
(n=64) 
 HR 95 % CI P value HR 95 % CI P value 
       1 1.16 1.03, 1.30 0.01 1.66 1.02, 2.71 0.04 
2 1.15 1.03, 1.30 0.02 1.20 0.96, 1.50 0.10 
3 1.14 1.02, 1.28 0.03 1.16 0.94, 1.43 0.17 
       4 1.13 1.01, 1.27 0.04 1.16 0.93, 1.43 0.19 
5 1.13 1.01, 1.27 0.04 1.14 0.92, 1.40 0.24 
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Table 3. Unadjusted and adjusted hazard ratios (95 % confidence interval) for all-cause and cardiovascular disease mortality at the cut-
points of >5, >10 or > 15mm Hg in systolic blood pressure (n = 4419) adjusted for CVD risk factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model Interarm  
difference 
All deaths (n=246) Cardiovascular deaths (n=64) 
  HR 95 % CI % change a HR 95 % CI % change a 
   ref b    ref b   
Basic model  
(age and ethnicity adjusted) 
>5 1.30 1.01, 1.67  1.66 1.02, 2.71  
>10 1.47 1.02, 2.11  1.87 0.98, 3.59  
>15 1.40 0.69, 2.83  1.92 0.60, 6.14  
        
Basic model plus  
lifestyle  
>5 1.30 1.01, 1.68 0 1.67 1.03, 2.74 -1.51 
>10 1.43 0.99, 2.06 9.30 1.82 0.95, 3.52 5.75 
 >15 1.49 0.74, 3.02 -22.5 2.03 0.64, 6.52 -11.96 
        
Basic model plus  
hypertension status 
>5 1.28 0.99, 1.65 6.67 1.62 1.00, 2.66 7.58 
>10 1.40 0.98, 2.02 16.28 1.76 0.92, 3.39 12.64 
 >15 1.30 0.64, 2.60 25.00 1.74 0.54, 5.99 19.57 
        
Basic model plus  
metabolic syndrome  
>5 1.28 0.99, 1.65 6.67 1.66 1.02, 2.71 0 
>10 1.35 0.93, 1.94 27.90 1.79 0.94, 3.45 9.20 
 >15 1.37 0.68, 2.77 7.5 1.80 0.94, 3.45 13.04 
        
Basic model plus  
ABI ≤0.9 
>5 1.29 1.00, 1.66 3.4 1.65 1.01, 2.70 3.03 
>10 1.44 1.01, 2.08 6.97 1.86 0.97, 3.56 1.15 
 >15 1.32 0.65, 2.67 20.00 1.85 0.58, 5.93 7.60 
        
Basic model plus  
Framingham risk score 
>5 1.25 0.98, 1.61 16.67 1.56 0.96, 2.56 15.15 
>10 1.38 0.96, 1.98 20.90 1.64 0.86, 3.16 35.94 
>15 1.27 0.63, 2.57 32.50 1.61 0.50, 5.12 33.70 
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HR = hazard ratio; CI = confidence interval. a ([Hazard Ratio adjusted for age and ethnicity − 1] − [Hazard Ratio adjusted for age and ethnicity plus covariate − 
1]/[Hazard Ratio adjusted for age and ethnicity − 1]) X 100.b Reference category = interarm difference in systolic blood pressure <5; <10; <15 depending 
on the analysis. 
Table 4. Model Fit and Calibration Estimates for mortality according to interarm differences in systolic blood pressure with and 
without the addition of Framingham Risk Score (n = 4419) 
 
a Harrell’s C Index, an adaptation of the C statistic (a generalization of the area under the receiver operating characteristic curve) in logistic 
models with higher values indicating better discrimination; c-statistics are corrected for over optimisim using from 100 bootstrap repetitions. b 
Akaike’s Information Criterion is a likelihood-based measure in which the -2 times the log-likelihood is penalized for the number of predictors 
in the model. Lower values indicate better prediction. c Bayes Information Criterion is similar to Akaike’s Information Criterion but imposes a 
more severe penalty for the number of predictors. Lower values indicate better prediction. 
 All deaths (n=246) 
  Model Fit  Models Penalized for Model Complexity 
Model C Index, 95% CI a Likelihood Ratio Test Akaike’s Information  
Criterion b 
Bayes Information  
Criterion c 
  χ 2 P-value   
FRS 0.60 (0.56, 0.63) 34.89 <0.001 2232.53 2251.71 
FRS plus IAD 5  0.60 (0.56, 0.63) 38.10 <0.001 2231.24 2256.81 
FRS plus IAD 10 0.60 (0.56, 0.64) 37.85 <0.001 2231.58 2257.16 
FRS plus IAD 15 0.60 (0.56, 0.64) 35.19 <0.001 2234.23 2259.81 
FRS plus IAD Per 10 mmHg 
 
0.60 (0.56, 0.64) 39.08 <0.001 2230.35 2255.93 
 Cardiovascular deaths (n=64) 
FRS 0.70 (0.64, 0.77) 40.40 <0.001 694.90 714.08 
FRS plus IAD 5  0.71 (0.64, 0.77) 43.76 <0.001 693.56 719.13 
FRS plus IAD 10 0.71 (0.64, 0.78) 42.60 <0.001 694.70 720.28 
FRS plus IAD 15 0.70 (0.64, 0.77) 40.98 <0.001 696.32 721.89 
FRS plus IAD Per 10 mmHg 
 
0.71 (0.64, 0.77) 41.91 <0.001 695.40 720.97 
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Figure 1. Distribution of interarm differences (mean of right arm minus mean of left arm) in systolic blood pressure  
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